<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940118-0-00019</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;4.115b <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Ratings of the genitourinary system_diagnoses. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 2,L2,tp0,p8,8/9,i1,s25,5 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 --> &blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1&blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Rating <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7500&blank;Kidney, removal of one: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Minimum evaluation <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 30 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Or rate as renal dysfunction if there is nephritis, infection, or pathology of the other. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7501&blank;Kidney, abscess of: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Rate as urinary tract infection <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 30 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7502&blank;Nephritis, chronic: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7504&blank;Pyelonephritis, chronic: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction or urinary tract infection, whichever is predominant. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7505&blank;Kidney, tuberculosis of: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate in accordance with &sect;&sect;4.88b or 4.89, whichever is appropriate. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7507&blank;Nephrosclerosis, arteriolar: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate according to predominant symptoms as renal dysfunction, hypertension or heart disease. If rated under the cardiovascular schedule, however, the percentage rating which would otherwise be assigned will be elevated to the next higher evaluation. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7508&blank;Nephrolithiasis: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as hydronephrosis,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> except for  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> recurrent stone formation requiring one or more of the following: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> 1. diet therapy <!-- PJG 0012 frnewline --> 2. drug therapy <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> 3. invasive or non-invasive procedures more than two times/year <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 30 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7509&blank;Hydronephrosis: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Severe; Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=03 g=1 f=1 --> Frequent attacks of colic with infection (pyonephrosis), kidney function impaired <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 30 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Frequent attacks of colic, requiring catheter drainage <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 20 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Only an occasional attack of colic, not infected and not requiring catheter drainage <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 10 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7510&blank;Ureterolithiasis: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as hydronephrosis,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> except for  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> recurrent stone formation requiring one or more of the following: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> 1. diet therapy <!-- PJG 0012 frnewline --> 2. drug therapy <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> 3. invasive or non-invasive procedures more than two times/year <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 30 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7511&blank;Ureter, stricture of: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as hydronephrosis,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=3 --> except for  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> recurrent stone formation requiring one or more of the following: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> 1. diet therapy <!-- PJG 0012 frnewline --> 2. drug therapy <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> 3. invasive or non-invasive procedures more than two times/year <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 30 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7512&blank;Cystitis, chronic, includes interstitial and all etiologies, infectious and non-infectious: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as voiding dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7515&blank;Bladder, calculus in, with symptoms interfering with function: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as voiding dysfunction <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7516&blank;Bladder, fistula of: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as voiding dysfunction or urinary tract infection, whichever is predominant. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Postoperative, superapubic cystotomy <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 100 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7517&blank;Bladder, injury of: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as voiding dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7518&blank;Urethra, stricture of: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as voiding dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7519&blank;Urethra, fistual of: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as voiding dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Multiple urethroperineal fistulae <!-- PJG 007 0104 intable --> 100 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> 7520&blank;Penis, removal of half or more <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 30 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Or rate as voiding dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> 7521&blank;Penis removal of glans <!-- PJG 007 0104 intable --> 20 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Or rate as voiding dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> 7522&blank;Penis, deformity, with loss of erectile power <!-- PJG 007 0104 intable --> 20 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7523&blank;Testis, atrophy complete: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Both <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 20 <!-- PJG 0012 frnewline --> One <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 0 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7524&blank;Testis, removal: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Both <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 30 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> One <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 0 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=2 --> Note <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> _In cases of the removal of one testis as the result of a service-incurred injury or disease, other than an descended or congenitally undeveloped testis, with the absence or nonfunctioning of the other testis unrelated to service, an evaluation of 30 percent will be assigned for the service-connected testicular loss. Testis, undescended, or congenitally undeveloped is not a ratable disability. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7525&blank;Epididymo-orchitis, chronic only: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as urinary tract infection. <!-- PJG 0012 frnewline --> For tubercular infections: Rate in accordance with &sect;&sect;4.88b or 4.89, whichever is appropriate. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7527&blank;Prostate gland injuries, infections, hypertrophy, postoperative residuals: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as voiding dysfunction or urinary tract infection, whichever is predominant. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> 7528&blank;Malignant neoplasms of the genitourinary system <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 100 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=2 --> Note <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> _Following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of &sect;3.105(e) of this chapter. If there has been no local reoccurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7529&blank;Benign neoplasms of the genitourinary system: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as voiding dysfunction or renal dysfunction, whichever is predominant. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7530&blank;Chronic renal disease requiring regular dialysis: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7531&blank;Kidney transplant: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Following transplant surgery <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 100 <!-- PJG 0012 frnewline --> Thereafter: Rate on residuals as renal dysfunction, minimum rating <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 30 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=2 --> Note <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> _The 100 percent evaluation shall be assigned as of the date of hospital admission for transplant surgery and shall continue with a mandatory VA examination one year following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of &sect;3.105(e) of this chapter. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7532&blank;Renal tubular disorders (such as renal glycosurias, aminoacidurias, renal tubular acidosis, Fanconi's syndrome, Bartter's syndrome, related disorders of Henle's loop and proximal or distal nephron function, etc.): <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Minimum rating for symptomatic condition <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 20 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Or rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7533&blank;Cystic diseases of the kidneys (polycystic disease, uremic medullary cystic disease, Medullary sponge kidney, and similar conditions): <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7534&blank;Atherosclerotic renal disease (renal artery stenosis or atheroembolic renal disease): <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7535&blank;Toxic nephropathy (antibotics, radiocontrast agents, nonsteroidal anti-inflammatory agents, heavy metals, and similar agents): <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7536&blank;Glomerulonephritis: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7537&blank;Interstitial nephritis: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7538&blank;Papillary necrosis: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7539&blank;Renal amyloid disease: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7540&blank;Disseminated intravascular coagulation with renal cortical necrosis: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7541&blank;Renal involvement in diabetes mellitus, sickle cell anemia, systemic lupus erythematosus, vasculitis, or other systemic disease processes. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as renal dysfunction. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7542&blank;Neurogenic bladder: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=1 --> Rate as voiding dysfunction. <!-- PJG /ITAG -->  </TABLE>  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;1045 Filed 1&hyph;14&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 8320&hyph;01&hyph;P <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            